The success of RNA interference (RNAi) depends on the interaction between short interference RNAs (siRNAs) and mRNAs. Design of highly efficient and specific siRNAs has become a challenging issue in applications of RNAi.
INTRODUCTION
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism during which doublestrand RNAs (dsRNAs) block the expression of endogenous mRNA by complementary interactions with their mRNA targets [1] . The process of RNAi can be summarized as follows: The Dicer enzyme binds a dsRNA and cleaves it into 21$23 nt fragments called 'short interference RNA' (siRNA) [2] ; Then the siRNA gets incorporated into the RNA-induced silencing complex (RISC) [3] and separated into the guide strand (antisense to the target mRNA) staying in the RISC, and the passenger strand (sense to the target mRNA) released and degraded soon; Next, the siRNA-RISC complex recognizes the target mRNA and triggers either degradation or translational repression of the mRNA depending on the degree of complementarity between the guide strand and the target [4] . Due to its simplicity, high efficacy and low cost, RNAi has a wide range of applications such as gene function studies, drug target discovery and disease treatments [5] [6] [7] [8] [9] .
The success of RNAi depends on specific interactions between siRNA and mRNA. However, the silencing ability of different siRNAs varies widely. Design of highly efficient and specific siRNA has become a major challenge in effective applications of RNAi [8] . From the computational perspective, the key issue in in silico siRNA design is how to choose a specific region in a target mRNA sequence as the passenger strand of the planned siRNA and then obtain its guide strand with efficient silencing ability. Currently, silencing efficacy and binding specificity represent the two most important issues in in silico siRNA design. Here, efficiency refers to the extent of the target mRNA molecules that can be inhibited by a siRNA, while specificity represents the percentage of the inhibited mRNAs that is not targeted when designing a siRNA, which is equivalent to as avoiding the 'off-target' effect (OTE). These two are the primary concerns in designing siRNAs and a number of research groups have developed criteria to address them when designing siRNA [10] [11] [12] [13] [14] . Although these criteria have helped to advance the state-of-the-art in silico siRNA design, several challenging problems remain to be addressed based on a number of recent studies [10, 15, 16] . These issues are mostly related to the insufficient RNAi data in the public domain, heterogeneous data types due to different platforms in data generation and inadequate consideration of the specificity of target mRNAs. We believe that the current criteria for siRNA design do not meet the need adequately in designing highly specific silencing RNAs, which has limited the scope of applications of RNAi. Based on these considerations, we further discuss the possible ways to address some of these issues. In this article, we will first present a comprehensive survey of the state-of-art in silico siRNA design strategies and then discuss issues that we are facing in order to design more efficient and more specific siRNAs as well as the possible ways to address them. Our particular focus is on integration of siRNA data from different platforms and on discussion of new integration schemes of heterogeneous siRNA data, based on advanced statistical learning techniques, to improve the efficacy and specificity of RNAi.
AN OVERVIEW ON RECENT STUDIES OF IN SILICO SIRNA DESIGN
From a computational perspective, discovery of in silico siRNA design rules and construction of siRNA efficacy prediction models have been the main focuses in RNAi studies. Its development history can be generally categorized into three periods.
2002-2004 was the period for identifying the basic siRNA design rules. Several rules for rational design for siRNAs were proposed by different groups, such as Tuschl [17] , Reynolds [14] , Chalk [12] and Amarzguioui [11] (see Table 1 ). These design rules had strong impact on the first generation of rational design methods of siRNA, which were mostly based on the information of GC content, preference or avoidance of specific nucleotides at specific positions and siRNA sequence motifs. One limitation of the methods developed during this period is that there was very limited siRNA efficacy data, hence there was no simple way for the developers to get feedback on their methods or validate them efficiently. Overall these methods lack effective ways to assess the statistical significance of their predicted siRNAs.
2005-2008 was the period for continued studies of siRNA design by increasingly more research groups. More advanced statistical and machine learning methods were developed for siRNA efficacy analyses, which led to the development of more reliable and robust siRNA design rules (see Table 2 ). These methods were based on techniques such as support vector machine [20] , self-organizing map [21] , neural networks [22] , decision trees [23] and various kernel methods [24] . Table 3 summarizes the siRNA design tools developed during this period. In addition, during the same time, a number of RNAi data sets with siRNA sequences as well as their application efficacy data were published and organized as databases in the public domain (see Table 4 ). Among these databases, the Novartis data set, containing 2431 siRNA sequences [22] , emerged as a popular data set used for tool development and validation. With the increase of siRNA data in the public domain, several novel siRNA design rules have been proposed, which mostly focus on the secondary structure of siRNAs and target mRNAs and take the binding free energy between them into consideration [25, 26] . The new techniques have considerably advanced the state of the art in designing more effective siRNAs, while a few challenging problems remain. First, the RNAi data sets in the public domain were typically generated by different groups possibly using different platforms. It has been observed that the developed siRNAs may have different efficacies when applied in different platforms, i.e. not having an identical conditional distribution possibly due to: (i) different assays/platforms/ scales were used for measuring the siRNA efficacy, against different cell types (Hela, fibroblasts) using test methods (Western Blotting, real-time PCR) or siRNA delivery methods (vectors method versus synthetic oligos method), (ii) very different concentrations and forms of siRNAs were used in different experiments (i.e. data using categorical or continuous values when measuring the siRNA efficacy and data Hsieh et al. [19] using sense or antisense strand and different nucleotide length to display siRNA sequences) and (iii) large differences in sub-optimal time intervals between transfection and down-regulation measurement; As a result, the design rules proposed by different groups may be inconsistent. For instance, Elbashir et al. [13] suggested that the sequence GC content between 32% and 79% could be the optimal range for siRNA design, while other groups like Reynolds et al. [14] and Amarzguioui et al. [11] suggested that this range should be 30-55%. 2009-2012 is a period with rapid advancement in siRNA design and in RNAi technologies. Compared with the former periods, studies during this period began to focus on high-throughput RNAi screening [59, 60] , reducing RNAi OTEs by siRNA chemical modifications [61, 62] , identifying relations among siRNAs and other small RNAs [63, 64] , siRNA therapeutic delivery [65, 66] and large-scale RNAi data integration and improved feature selection. On high-throughput RNAi screening and data integration, Karlas et al. [59] used a genome-wide RNAi screen and discovered 287 human genes that can influence influenza A virus replication, highlighting the power of genome-wide RNAi screening for elucidation of virus-host interactions and identification of potential drug targets for a broad range of influenza viruses. Klingelhoefer etal.
[16] developed a meta-data set of 6483 siRNAs by integrating 9 RNAi data sets, based on which they Vert et al. [30] identified a number of novel features associated with siRNA efficacy. With such data integration and computational model advancing, the classical siRNA design rules are updated and the most common ones are listed in Table 5 . In the meantime, the OTE of siRNAs has become a focal point in assessing the efficacy of siRNAs as this can cause significant side effects when used on human [67, 68] . Currently, the OTEs include the following: (i) siRNA-induced sequence-dependent regulation of unintended transcripts through partial sequence complementarity to their 3 0 -UTRs (microRNA-like OTEs), (ii) an inflammatory response through activation of Toll-like receptors triggered by siRNAs and/or their delivery vehicles (such as cationic lipids) and (iii) widespread effects on microRNA processing and function through saturation of the endogenous RNAi machinery by exogenous siRNAs [68] . In order to reduce the OTEs of siRNAs in therapeutic applications, siRNA chemical modifications have been applied to increase the stability and specificity of siRNAs. The most significant siRNA modifications described in literature can be classified into six types [69] : (i) 'base modification', to improve target recognition and reduce immune activation, (ii) 'sugar modification', to introduce unlocked nucleic acid monomer to enable modulation of the thermodynamic stability of siRNAs, (iii) 'backbone modifications', to introduce modifications such as phosphorothioate bonds at desired positions to prolong the life of the RNA duplex when exposed to serum or other nuclease sources, (iv) 'architecture modifications', to modify the RNA duplex architecture to convert siRNA to other architectures like Dicer-substrate siRNA, asymmetric siRNAs and small internally segmented interfering RNAs, (v) 'modifications to overhangs and termini', to adjust the unwinding of the siRNA duplex, incorporation of the siRNA into RISC and/or the rate of target cleavage and product release and (vi) 'conjugations', to improve thermodynamic and nuclease stability, bio-distribution and pharmacokinetic profiles of siRNAs, as well as cellular uptake without perturbing gene silencing activity. Studies during this period have also revealed that the effect of siRNAs on target genes is not only influenced by site-specific factors but also by more general factors of the target mRNAs such as their cellular abundance and turn-over rates [70, 71] . Other studies have also been carried out to examine relations among siRNAs, and other small RNAs like miRNA and piRNA (Piwi-interacting RNA, which comes from RNA-protein complexes through interactions with piwi proteins [64] ), to uncover the differences in their mechanisms of gene silencing [63, 64, 72] . Such studies could help people to further understand the RNAi mechanism as well as the inside characteristic of RISC for different small RNA molecules. Table 6 summarizes comparisons between characteristics of siRNA, miRNA and piRNA for target silencing. One particular problem here is the 'RNA sorting' problem, which studies the influence of binding proteins on different small RNAs in ribonuclear complex [73] [74] [75] . Such studies may provide Wang et al. [77] novel ways to improve the RNAi efficacy from the perspective of binding protein structures.
It should be noted that the elimination of OTEs also substantially depends on the siRNA delivery strategy substantially, which plays an important role in disease treatment, especially for cancer therapy. To overcome the severe safety risks caused by the viral delivery vectors due to their oncogenic potential and their inflammatory and immunogenic effects, nonviral delivery vectors have become a prospective alternative for siRNA delivery. This technology can be catalogued into several types, including 'hydrodynamic injection', 'cholesterol conjugation with siRNA', 'cationic delivery systems', 'selfassembled LPD nanoparticles' and others [66] . Among these methods, the latest progress in the study of siRNA delivery is focused on the development of nanoparticle delivery and peptide delivery systems. Lee et al. [90] showed that self-assembled DNA tetrahedral nanoparticles with cancer-targeting ligands (such as peptides and folate) on the nanoparticle surface can deliver siRNAs into cells and silence target genes in tumors. Lee et al. [91] reported an approach called RNAi-microsponges, consisting entirely of cleavable hairpin RNAs which can be converted to siRNA only after cellular uptake, thus inherently providing protection for siRNA during delivery and transport to the cytoplasm. Yao et al. [92] discovered that the Polo-like kinase 1 siRNAs complexed with a Her2-ScFv-protamine peptide fusion protein (F5-P) could suppress Her2 þ breast tumor growth, reduced metastasis and prolonged survival without evident toxicity. We will not go into further details here since most of these technologies involve synthetic biology applications which are beyond the scope of the current article, but we do believe that more and more computational methods will be taken into consideration in this area.
PROBLEMS AND POSSIBLE SOLUTIONS WITH THE CURRENT
IN SILICO SIRNA DESIGN PARADIGM Inconsistencies among different siRNA design rules and incomplete feature set of siRNA
The inconsistency issues with the current siRNA design rules are mostly due to the heterogeneity of the siRNA data. Although some studies have pointed out this issue, there exist limited published studies which tackle this problem in a systematic manner. As discussed earlier, the fundamental issue is that there is lack of an effective way to bring all the heterogeneous data into the same framework so that results based on them can be directly comparable. Due to this reality, the design rules derived based on different data sets are not universally applicable. Clearly by searching through all 4 19 (the typical length of a siRNA is 19 nt) possible combinations of siRNA sequences to assess their application efficacy can help to derive effective design rules but this is computationally intractable. The Max-PlanckInstitute (MPI) principle (Table 1) is an effort aiming to identify all key features relevant to siRNA design, which include the GC content and two overhangs in 3 0 in siRNA strands as important features. However, studies have shown that considerable siRNAs designed according to MPI principle are not effective, having a high false positive rate [93] . Recently, a meta-rules ensemble strategy was presented to improve the siRNA design, by integrating several factors, meta design rules as well as filter criteria and reported a 98% rejection of false positive siRNAs, showing superiority over traditional state of the art siRNA design programs [94] . Besides such a rule ensemble strategy that provides an efficient way to alleviate the inconsistencies among different [62, 86, 88, 89] siRNA design rules, the inconsistencies among different siRNA design strategies can also be addressed by the integration of different heterogeneous siRNA data sources, which will be discussed in the next section.
Improper integration of the cross-platform siRNA data
While efforts have been invested into integration of different data sets to improve the design rules, the siRNA efficacy for different platforms cannot be easily compared as we have demonstrated before, which makes integration of heterogeneous data sets very challenging [95] . The issues of heterogeneity and non-identical underlying conditional distributions among different data sets have largely been ignored in many previous studies, even in highly popular data set such as [15] , which has been used as a benchmark for training and testing in several studies for siRNA efficacy prediction [95] . It should be noted that the data integration issue is non-trivial. Klingelhoefer et al. [16] pioneered such work by first constructing a meta-data set of 6483 publicly available siRNAs (targeting mammalian mRNA) and then applying a Bayesian analysis to accommodate feature set uncertainty. They pointed out that the task of combining data from heterogeneous sources into a single meta-analysis study is not straightforward. The inconsistency in measuring and reporting siRNA potency and the mixture of sense or antisense strand siRNA sequences remains two obstacles, which may lead to incomparable results of different RNAi. To tackle this problem, they adapted a simple normalization strategy to re-format all the continued siRNA activity data [16] . Following their work, our group recently further demonstrated that simple-minded integration strategies such as data normalization of heterogeneous RNAi data sets can provide only very limited gain or even loss in improving siRNA efficacy prediction. In our study, we first compiled 10 cross-platform heterogeneous siRNA data sets. A baseline method was applied by randomly selecting 50% of the data from each data set as the training data to train a linear ridge regression model and then testing 50% of the data. The process was repeated 10 times and the average RMSE for each data set was calculated. This baseline strategy was compared with another test strategy, in which the same procedure was applied except that we treated each data set as target data set, respectively and we randomly selected 50% of the data in target data set to combine with all the data in other data sets (source data set) as training data to train the model and tested it on the remain 50%. We found that even when all the data were normalized in the same range [0,1] and the data from source data sets were added to the training data, the prediction accuracy was still not improving. Moreover, worse results in almost half of the data sets were found, which indicated that simple combination and normalization of cross-platform data source may provide little improvement on the siRNA efficacy prediction of a particular platform [95, 96] .
To address this problem, our group proposed a multi-task learning-based method [95] to integrate heterogeneous siRNA data. The simple idea behind our solution is that we just take each siRNA data source as a 'task' and we aim at learning a joint efficacy prediction model for all the given siRNA data sets simultaneously rather than focusing on a specific individual data set to learn a regression model for the efficacy prediction and design rules derivation. Such integrative learning model has its theoretical basis and advantages for data integration, by exploiting the possible synergies across different data sets rather than using a single data set or combining them directly. Our preliminary results also indicated that multi-task learning model has a remarkably better prediction performance compared to the traditional regression models on individual siRNA data independently and thus help to derive more robust siRNA design rules [76] .
Besides our proposed methods, another possible solution to address the issue of heterogeneous data integration is to introduce or build the unified framework for siRNA data uploading, storage, query, administration. This would greatly facilitate the replication of reported results and data sharing between different groups. Among this field, minimum information about an RNAi experiment (www.miare.org) presents a set of guidelines on the information that should be reported for every RNAi experiment, which is a significant step toward this direction [16] .
Inadequate consideration of the specificity of target mRNAs
It is known that small RNAs, such as microRNAs and siRNAs, can down-regulate hundreds of target genes. Targeting determinants not only include many site-specific factors such as base-pair complementarity and destabilization signals but also include many system-level factors, like the turn-over rates of the mRNAs, their locations in the molecular complexes etal. which were discussed in our previous work [95] , Arvey's work or Larsson's work [70, 71] . For these reasons, two different mRNAs with the same siRNA-binding region as well as the same secondary structures may have different binding efficacies with a siRNA. Such global properties of target mRNA influence the siRNA efficacy and should be taken into consideration for siRNA design. Among this area, Arvey et al. [70] hypothesized that siRNAs that have a higher number of available target transcripts will down-regulate each individual target gene to a lesser extent than those with a lower number of targets and this phenomenon was referred to as 'dilution effect' as those small RNAs with many targets have their effect diluted across many molecules. Based on this point, it is easy to reason that the effect of siRNAs on each individual gene may be modulated by target transcript abundance. Larsson et al. [71] also pointed out that mRNAs with high turnover rates may be more resistant to RNAi-mediated silencing, short-lived transcripts are more difficult to silence using siRNAs and this can be contributing to the interpretation of why certain transcripts are inherently recalcitrant to perturbation by small RNAs. Overall, global properties of mRNA do play an important role in determining the binding efficacy of a siRNAs. Researches in this field are only in their beginning.
From a computational perspective, if the global properties of target mRNA were considered, the general siRNA design guidelines and efficacy prediction models would need to be re-considered and improved in a 'granularity' of mRNA, that is, it is better to compile siRNA affinity data targeted on the same mRNA to build the prediction model, rather than traditionally mixing the data from different targets, since siRNA affinity targeted on other mRNAs may bias the design on the current target. This can be analogous to the Quantitative Structure Activity Relationship (QSAR) study in chemistry community [97] , where the molecules binding to one target should have a specific QSAR model for biological activity prediction rather than mixing all the targets together. From this point of view, the siRNAs binding to a specific mRNA may also contain inherent characteristic we may not uncover and should hold their own efficacy predictive model.
With this idea in mind, our group recently proposed a target specific siRNA design based on domain transfer in heterogeneous data [96] . The key point here is that when the target specificity is concerned, the siRNA affinity prediction model should be built based on a 'granularity' of mRNA. Nevertheless, we found that when each mRNA and its existing binding siRNA was treated as an independent data set, the general problem faced here is that commonly the number of experimental RNAi data toward a specific target mRNA is small and they are insufficient to train an accurate predictive model or derive statistical significant design rules for more efficient and specific siRNAs design. To overcome this problem, we treat the siRNA data on each specific target as different task or domain and formulated the target-specific siRNA design as a transfer learning-based heterogeneous regression problem [96] , that is, we treat the siRNA data on each specific target as different task or domain and 'unify' them to perform 'knowledge transfer' across the domain/task, which helps to solve the data sparseness within a specific domain/task. In summary, such a transfer learning strategy can not only help to improve the target siRNA efficacy modeling but also help to select more target-gene-related features for siRNA design, which was also addressed in our recently submitted work [96] .
Off-target effects in siRNA design
The OTEs can occur through sequence identity of either strand of the duplex with an mRNA that is not the intended target. An excessively high concentration of siRNA, 100 nM or higher, can also cause non-specific off-target activity. Several studies have focused on designs which reduce off-target liabilities [68, [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] (Table 7) . Among them, pooling of multiple siRNAs to the same target ('siRNA pool') may serve as an efficient method to reduce off-target silencing [109] . A workable industry example of this technique is the Dharmacon SMARTselection reagent for RNAi, which consist of four SMARTselection designed duplexes, targeting different sequences of the same mRNA, combined into one reagent. The advantages of such siRNA pool reagent lies in the 'effective concentration' of the duplexes in the pool: at a total siRNA concentration of 100 nM, the individual duplexes comprising the pool are at a much lower concentration, $25 nM. Thus, the off-target activity of each duplex is reduced by a concentration dependent mechanism [109] , while their overall silencing ability is maintained with individual adduct.
In the design of siRNA pool, a more complex and efficient way to limit OTE from target mRNA perspective is to consider multiple fragments of the target gene highly homologous to other genes as the templates to design multiple siRNA sequences and pool them together with low concentrations. At a first glance, this may increase the number of OTEs as each siRNA may bind to more non-target genes. However, Arvey et al. and Larsson et al. [70, 71] discovered that the binding efficacy is negatively correlated to the abundance of off-targets, which means that the binding efficacy to off-targets will be diluted when the number of off-targets increased. In other words, this will reduce RNAi-induced toxicity for individual siRNA, which is also proven by Anderson et al. [110] . Since with the increased number of off-targets, the siRNA binding efficacy to primary target is also diluted, the pool of such multiple siRNAs at low concentrations will serve as a remedy by individual adduct. Finally, the required silence ability of such mixed siRNA pooling is maintained as one unit, and at the same time, with reduced toxicity and OTEs for individual siRNA among them.
To sum up, it can be seen that the issues discussed here and in 'Inconsistencies Among Different siRNA Design Rules and Incomplete Feature Set of siRNA', 'Improper Integration of the Asymmetric siRNAs with shortened sense strand [107, 108] Potential reduction of siRNAs stability.
Cross-Platform siRNA Data' and 'Inadequate Consideration of the Specificity of Target mRNAs' sections are related. They are mainly related to the effective integration and utilization of the information derived from different sources of the heterogeneous RNAi data to build prediction models that can produce desired siRNAs with higher specificity and higher efficacy. It is encouraging to see various efforts have been put on these issues but clearly we are still in its infancy. As a summary here we also formulate a general computaional pipeline based on integrated heterogeneous data and advanced machine learning techniques aforementioned for in silico siRNA design. Specifically, we carry out an effective data integration strategy through combining 'multi-task learning' and 'transfer learning' in the area of advanced statistical learning. The whole computational siRNA screening scheme is presented in Figure 1 . In brief, this scheme contains several processes about integration of heterogeneous data, construction of multi-platform siRNA efficacy prediction model, joint siRNA feature selection and siRNA design for specific target genes. The mainline of the project is listed in green textbox and the procedures shown in blue and yellow textboxes correspond to two parts: 'multi-task learning for heterogeneous data integration and feature selection' and 'transfer learning for customized siRNA screening toward specific target genes', respectively. In Stage 3 of the mainline, the features selected on the above two parts are aggregated to obtain the final siRNA design features and rules. Such feature aggregation takes the considerations of both the common factors and the specific properties of target genes, which is expected to improve the efficiency and specificity of siRNA design. Overall, we believe that this strategy may possibly provide new clues for solving the aforementioned problems from a computational perspective, while the current results are preliminary and issues like that of negative transfer in siRNA design [96] and how to select a proper siRNA template reamin. We hope that more collaborations of in vivo experiments with in silico technologies can be conducted in the future.
SUMMARY AND PROSPECTIVE
With the great potential of RNAi techniques and the continuous development of high-throughput RNAi screening, there is an urgent need to improve the state-of-the-art siRNA design rules as well as construct reliable siRNA efficacy prediction model. Here, a comprehensive review and analysis on the current problems we are facing in siRNA design was presented. Four key problems, i.e.: (i) inconsistencies among the proposed guidelines for siRNAs design and the incomplete list of siRNAs features, (ii) improper integration of the heterogeneous cross-platform siRNAs data, (iii) inadequate consideration of the binding specificity of the target mRNAs and (iv) reduction in the OTE in siRNAs design were summarized. Several novel computational siRNA screening techniques were proposed to solve these issues. While we anticipate that the new strategies will improve the state of the art in siRNA design, a number of issues require further investigation, among which an unified schema for RNAi data generation, storage, sharing and efficacy modeling across heterogeneous siRNA data are needed, which is a crucial step toward more efficient and specific siRNA design.
KEY POINTS
An overview on recent studies of in silico siRNA design are presented, which can be categorized into three periods: (i) the period for identifying the basic siRNA design rules, (ii) the period for continued studies of siRNA design by increasingly more research groups and (iii) the period with rapid advancement in siRNA design and RNAi technologies.
Four problems with the current in silico siRNA design paradigm are summarized: (i) inconsistencies among different siRNA design rules and incomplete feature set of siRNA, (ii) improper integration of the cross-platform siRNA data, (iii) inadequate consideration of the specificity of target mRNAs and (iv) possible ways to effectively reduce OTEs. Several novel computational schemes for siRNA design using state-of-art machine learning techniques are proposed, which focuses on heterogeneous data integration, joint feature selection and customized siRNA screening toward highly specific targets.
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